Database

Startups

Main Industry
Health Care
Main Product/Service
1. Healthy Intestines to Probiotics
2. Plant extract shampoo
Founded Year
2014
Unified Business No.
54802983
Status
Active
Number of Employees
0
Total Paid-in Capital
108,931,350 (NT$)
Location of Company
Taiwan , Hsinchu City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
About the Company
ARJIL Pharmaceuticals LLC, founded in 2014, is a clinical-stage biopharmaceutical company pioneering innovative therapies. Our pipeline focuses on botanical-based medicines and promising small molecule drug candidates, aiming to improve the health and well-being of aging individuals. As of 2024, Arjil‘s funding investment has exceeded 8 million US Dollars.



More ↓

Similar Companies

XANTHO BIOTECHNOLOGY CO., LTD.

*Botanical New Drug*
The main therapeutic area we are focusing on is dermatology. With the aim of improving the quality of life for patients, we develop products with market profitability and improved clinical effectiveness for patients in different age groups, thereby contributing to the well-being of human.
*Immunity and Inflammation*
The botanical new drug GM-XANTHO, a topical drug developed by Xantho Bio., is now in phase 2 study for atopic dermatitis (AD). GM-XANTHO is shown to be safe and well-tolerated in human, and it is expected to be more accessible to AD patients compared to injectables and oral drugs. It is anticipated that the results of the Phase IIa clinical study will be available in Q2 2025.